LY2874455

LY2874455 is an orally bioavailable, investigational small molecule that acts as a potent, selective pan-inhibitor of the fibroblast growth factor receptor (FGFR) family, targeting FGFR1, FGFR2, FGFR3, and FGFR4. By binding to the ATP-binding pocket of these receptors and inhibiting their kinase activity, it blocks downstream signal transduction pathways involved in tumor cell proliferation and angiogenesis. This mechanism results in inhibition of both tumor angiogenesis and proliferation in cancers with overexpression or dysregulation of FGFRs. Developed by Eli Lilly and Company for oncology indications—primarily advanced cancer—LY2874455 has demonstrated antineoplastic activity in preclinical models and has reached phase II clinical trials for cancer[1][2][3][4][5].

Other names

pan-FGFR inhibitor LY2874455FGF receptor inhibitor - Eli Lilly and CompanyUNII-E9M363811VUNII-E-9M363811VUNII-E 9M363811V1254473-64-7